Équipe de direction

Christopher Simon a été nommé PDG d'Haemonetics le 16 mai 2016. Il était auparavant Directeur Associé Senior au sein du cabinet de conseil McKinsey & Company ,où il a dirigé le pôle international dédié à l'équipement médical. Il possède plus de vingt ans d'expérience dans le développement et la transformation de l'activité commerciale.

Chris Simon a été le principal partenaire pour l'analyse stratégique d'Haemonetics lancée en octobre 2015, ce qui lui a permis de mieux connaître notre activité commerciale et nos marchés. Il a participé, avec le comité de direction et le conseil d'administration, à l'élaboration du plan stratégique que nous mettons actuellement en place.

Il a rejoint McKinsey en 1993. Avant cela, il a été occupé des postes commerciaux et opérationnels chez Baxter Healthcare Corporation et a également été officier d'infanterie de l'Armée américaine en Corée et appartenu au 1er bataillon de Rangers.

Chris est titualire d'une licence B.S. en économie de la Wharton School de l'Université de Pennsylvanie et d'un MBA de la Harvard Business School.

Michelle Basil joined Haemonetics in March 2017 as Executive Vice President, General Counsel. She is responsible for Haemonetics' Legal, Compliance and Corporate Audits and Controls groups.

Prior to joining Haemonetics, Ms. Basil was a Partner and Chair of the Life Sciences Practice Group at the Boston-based law firm Nutter, McClennen & Fish where she was legal counsel to public and private companies and their investors, principally in the life sciences and medical technology industries. At Nutter, Ms. Basil’s practice focused on corporate and securities law, including mergers and acquisitions, strategic collaborations, capital markets transactions, corporate governance and other matters affecting publicly traded companies and their officers and directors.

Ms. Basil is admitted to the bar in Massachusetts and holds both a Bachelor of Arts and a Juris Doctor from the University of California at Berkeley.

Bill Burke a rejoint Haemonetics comme directeur financier en août 2016. Il est responsable de l'organisation mondiale des finances, qui inclut les relations avec les investisseurs. Auparavant, M. Burke a été responsable et Vice-président de l'intégration lors de la fusion entre Medtronic et Covidien, après avoir occupé durant plus de neuf années divers rôles de direction financière chez Covidien, notamment : Directeur financier Europe, Vice-président stratégie d'entreprise et gestion de portefeuille et Vice-président analyse et planification financière.

Avant de travailler pour Covidien, il a également occupé plusieurs postes dans les domaines de l'analyse et de la planification financières et des audits au sein du groupe Tyco Healthcare. M. Burke est titulaire d'un Bachelor of Science in Business Administration obtenu à l'Université Bryant, avec une spécialisation en comptabilité ; il est en outre expert-comptable certifié.

Chad Nikel joined Haemonetics in 2009 as Site Director for the company’s Illinois facility, where he managed TEG operations, research and development, and marketing. In April 2011, he was promoted to Vice President, Global TEG, where he chartered a team in the global launch of the TEG product line and led an initiative to acquire a next generation technology for hemostasis monitoring. Mr. Nikel was promoted to Vice President, North America Blood Bank in September 2013, where he led commercial activities for the company’s Blood Center business and assumed global responsibility for the Whole Blood business in 2015. Mr. Nikel was promoted to Vice President, Global Blood Center, in 2017 and to his current role as President, Global Blood Center, in 2018.

Prior to joining Haemonetics, Mr. Nikel was Director, Strategy and Business Development at IPM Life Sciences. He previously held roles in research and development, operations and project management. Mr. Nikel began his career in the United States Air Force, where he served for five years and earned the rank of Captain.

Mr. Nikel holds a Bachelor of Science in both Civil Engineering and Environmental Engineering from the United States Air Force Academy and an MBA from St. Mary’s University.

Kevin O’Kelly-Lynch joined Haemonetics in December 2016 as Senior Vice President, Global Business Services. He has an extensive and seasoned background in global business and shared services spanning customer service and tech support, finance, procurement, IT, fleet and sales operations. He brings to Haemonetics the knowledge and experience to help the company successfully transform the way it creates enabling platforms to deliver critical services across multiple functions.

Mr. O’Kelly-Lynch most recently served as Vice President, Medtronic Business Services, where he led the Global Business Services Integration activity post the acquisition of Covidien, and managed a service delivery team of over 600 deployed in the United States, Europe and India. Prior to Medtronic, he was Vice President, Assistant Treasurer at Covidien plc, where he was responsible for global treasury operations. He has also held the position of International Treasurer & Managing Director at Tyco International, and Transfer Pricing Manager and Management Accountant at Diageo plc. He began his career at Fujitsu.

Mr. O’Kelly-Lynch received a Bachelor of Science in Management from Trinity College, Dublin and is a Chartered Global Management Accountant (CGMA).

Neil Ryding a rejoint Haemonetics en 2015 en tant que Vice-Président Directeur, Activités mondiales. Il possède plus de 30 ans d'expérience dans le domaine de la fabrication et des chaînes d'approvisionnement au niveau mondial dans les secteurs réglementés de l'aérospatiale et des dispositifs médicaux. Il a occupé divers postes exigeant un large éventail de compétences opérationnelles complexes dans le monde entier pour des sociétés internationales , telles que Rolls Royce Aero-Engines, Johnson & Johnson, Smith & Nephew, Cardinal Health et Hospira.

Dr. Purdy has more than 20 years of experience in medical devices and diagnostics spanning all regions of the world, along with extensive experience in new product submissions, particularly in China, Europe, Japan and the U.S.

Most recently, he was Vice President, Clinical Regulatory and Quality Compliance at Thermo Fisher Scientific since 2012. He was responsible for the oversight and coordination of worldwide regulatory and quality compliance, overseeing a team of 2,500 employees at more than 100 global sites. He also held numerous clinical, regulatory and quality roles of increasing scope at Boston Scientific between 2000 and 2012, playing a critical role in ensuring regulatory and quality excellence for innovation-based products. He began his career working in clinical research at Smiths Medical.

Dr. Purdy holds a doctorate in Human Physiology (Haemodynamics) from the University of Southampton and a Bachelor of Science in Applied & Human Biology from Aston University (both in the UK). He also holds an Advanced Certificate in Management, Innovation and Technology from MIT’s Sloan School of Management.

Jacqueline Scanlan joined Haemonetics in March 2017 as Senior Vice President, Human Resources. She is responsible for the global Human Resources and Communications functions, with a focus on driving talent management.

Previously, Ms. Scanlan was Corporate Vice President, Human Resources, North America at Novo Nordisk. In this role, she led all aspects of the organization and people strategy for North America, and served as a key member of the Executive Team. Her responsibilities included organization development as well as change and talent management. Prior to Novo Nordisk, she held various HR leadership roles at Campbell Soup Company, including International HR, Global Talent Management and Organizational Effectiveness, and HR Business Partner. Earlier in her career, Ms. Scanlan held HR and consulting roles at Bristol-Myers Squibb, DuPont Pharmaceuticals Company and Accenture.

Ms. Scanlan received a Bachelor of Arts in Political Science from St. Joseph’s University and a Master of Science in Organizational Dynamics from the University of Pennsylvania.

Francis “Frank” Tan joined Haemonetics in June 2017 as Senior Vice President, Corporate Development and Planning. He is responsible for all of Haemonetics’ business development activities, including partnerships, collaborations, and mergers and acquisitions.

Previously, Mr. Tan was Vice President, Corporate Development at Thermo Fisher Scientific. While there, he developed and executed strategic growth initiatives across the company’s multiple businesses, representing roughly $18 billion in total revenues. He also led the execution of over a dozen merger and acquisition transactions valued at more than $30 billion. Prior to Thermo Fisher, Mr. Tan was Director, Business Development at EMD Millipore and held leadership roles in the company’s integration office during Millipore’s acquisition by Merck KGaA. He has an extensive background across all types of external licensing and partnership relationships as well as corporate strategy, product management, private equity, and financial analysis.

Mr. Tan holds a Bachelor of Arts from Amherst College and an MBA in Finance and Strategy from the Yale School of Management.

David J. Wilson joined Haemonetics in September 2017 as President, Global Plasma. He is a proven business leader with more than 20 years of experience in senior leadership roles at medical technology companies. He is responsible for expanding and strengthening the company’s market position in the plasma industry.

Mr. Wilson was most recently President, Cordis (a Cardinal Health company), which he led from March 2015 through August 2017. Cordis is a nearly $1 billion business focused on cardiovascular devices that Mr. Wilson brought back to profitable sales growth during his tenure as President. Prior to Cordis, Mr. Wilson held positions of increasing responsibility at Johnson & Johnson driving sales, marketing, research and development, operations and business development. He also worked previously in plasma-based sciences both at Ethicon Biosurgery and at Cohesion Corporation.

Mr. Wilson received a Bachelor of Mechanical Engineering from Auburn University, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham, and an MBA from Columbia University.